← Eichor
Condition: Atopic Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Atopic

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.
Phase 2 · 12 location(s) · Alphyn Biologics · NCT06855745Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Level
Phase 2 · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT03835767Tolerance and Efficacy Open-label Study With RV4421B, in Various Populations With Atopic Dermatitis for 12 Weeks
NA · 1 location(s) · Pierre Fabre Dermo Cosmetique · NCT07014007Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammato
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06599411A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
Phase 2 · 62 location(s) · Janssen Research & Development, LLC · NCT07230860This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate
Phase N/A · 59 location(s) · Sanofi · NCT07290803Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Phase 2 · 23 location(s) · Enveda Therapeutics · NCT07298395Disease Trajectories and Anti-cytokine Response Signatures in Atopic Dermatitis and Psoriasis
Phase N/A · 1 location(s) · University Hospital Schleswig-Holstein · NCT03361215Multi-modal Quantitative Imaging of the Skin
Phase N/A · 3 location(s) · HJN Sverige AB/Neko Health · NCT06989216Determinants of Chronic Inflammatory Skin Disease Trajectories
Phase N/A · 1 location(s) · University Hospital Schleswig-Holstein · NCT05928169China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project
Phase N/A · 1 location(s) · Peking University First Hospital · NCT05316805FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Phase 1 · 5 location(s) · Pfizer · NCT06564389Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
Phase 3 · 1 location(s) · Jiangsu vcare pharmaceutical technology co., LTD · NCT06723080A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis
Phase 1 · 1 location(s) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · NCT07693738Drug Survival of Target Therapies in Atopic Dermatitis
Phase N/A · 1 location(s) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT06882148Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe At
Phase 2 · 99 location(s) · Novartis Pharmaceuticals · NCT06947993Lebrikizumab in Moderate-to-severe Atopic Dermatitis
Phase 4 · 4 location(s) · Johann E Gudjonsson MD PhD · NCT06906497Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)
Phase 1 · 8 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT06504160Efficacy Evaluation and Cutaneous Acceptibility of a Dermocosmetic Product on Subjects Suffering of Atopic Dermatisis.
NA · 1 location(s) · NAOS Les Laboratoires · NCT06756438A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection
Phase 1 · 1 location(s) · Jiangsu Genscend Biopharmaceutical Co., Ltd · NCT07411755Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis
Phase N/A · 1 location(s) · Zhongda Hospital · NCT07573735Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi
Phase 1 · 1 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT07262983Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy
Phase N/A · 9 location(s) · Fundación Academia Española de Dermatología · NCT05674695Registry for Systemic Eczema Treatments
Phase N/A · 1 location(s) · Johns Hopkins University · NCT06136767An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
Phase 3 · 19 location(s) · Dompé Farmaceutici S.p.A · NCT07395232Treatment and Medical Care of Patients With Moderate-to-severe Atopic Dermatitis - TREATswitzerland
Phase N/A · 9 location(s) · Swiss Society of Dermatology and Venereology · NCT05819463Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
Phase 3 · 30 location(s) · medac GmbH · NCT06239311The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit
Phase N/A · 7 location(s) · Sanofi · NCT07467564Deployment o the Multidisciplinary Prospective Cohort Imminent
NA · 1 location(s) · University Hospital, Lille · NCT04334031A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moder
Phase 2 · 2 location(s) · AbbVie · NCT06524635
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.